Zura Bio Announces Participation in June Investor Conferences

Rhea-AI Summary

Zura Bio, a clinical-stage immunology company with a focus on novel dual-pathway antibodies for autoimmune and inflammatory diseases, announced participation in two June investor conferences. Chief Scientific Officer Michael Howell will attend one-on-one meetings at the Jefferies Global Healthcare Conference on June 6, 2024, in New York. CEO Robert Lisicki will participate in a panel discussion on dermatological disorders and hold one-on-one meetings at the Oppenheimer Novel Targets in Immunology Summit on June 24, 2024, in New York. These events aim to strengthen investor relations and provide insights into Zura Bio's innovative clinical programs.

Positive

• Participation in prominent investor conferences can enhance visibility and credibility among investors.
• CEO and CSO engagement in one-on-one meetings may attract potential partnerships and investments.
• Panel discussion participation highlights Zura Bio's expertise in immunological mechanisms for dermatological disorders.

Negative

• No new clinical data or financial results were disclosed in the press release.
• Potential over-reliance on investor conferences without immediate tangible outcomes could be seen as a risk.

HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of senior management will participate in two investor conferences in June.

Conference Details:

Event: Jefferies Global Healthcare Conference
Details: Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Medicine, will participate in one-on-one meetings on Thursday, June 6, 2024, in New York, NY.

Event: Oppenheimer Novel Targets in Immunology Summit
Details: Robert Lisicki, Chief Executive Officer, will participate in a “Novel Immunological Mechanisms for Dermatological Disorders” panel discussion and one-on-one meetings on Monday, June 24, 2024, in New York, NY.

ABOUT ZURA BIO

Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880), with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240529218969/en/

Megan K. Weinshank

Head of Investor Relations

ir@zurabio.com

Lee M. Stern

Meru Advisors

lstern@meruadvisors.com

Source: Zura Bio Limited

FAQ

What conferences will Zura Bio attend in June 2024?

Zura Bio will attend the Jefferies Global Healthcare Conference on June 6, 2024, and the Oppenheimer Novel Targets in Immunology Summit on June 24, 2024.

Who will represent Zura Bio at the Jefferies Global Healthcare Conference?

Michael Howell, Chief Scientific Officer, will represent Zura Bio with one-on-one meetings on June 6, 2024.

What is the focus of the panel discussion that Zura Bio's CEO will participate in?

The panel discussion will focus on 'Novel Immunological Mechanisms for Dermatological Disorders'.

When will Zura Bio's CEO participate in the Oppenheimer Novel Targets in Immunology Summit?

Zura Bio's CEO, Robert Lisicki, will participate on June 24, 2024.